reports
Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidat...
Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron Omicron-adapted monovalent candidate given as a fourth booster dose elicited a 13.5 and 19.6-fold increase in neutralizing geometric titers against Omicron BA.1 at 30 µg and 60 µg dose levels; bivalent vaccine candidate exhibited a 9.1 and 10.9-fold increase against Omicron Geometric mean ratios for Omicron neutralizing antibody response consistent with regulatory requirement of superiorityPreliminary laboratory studies demonstrate both Omicron-adapted candidates neutra...
Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidat...
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- (NYSE: PFE) and (Nasdaq: BNTX) today announced positive data evaluating the safety, tolerability, and immunogenicity of two Omicron-adapted COVID-19 vaccine candidates: one and the other bivalent, a combination of the Pfizer-BioNTech COVID-19 Vaccine and a vaccine candidate targeting the spike protein of the Omicron BA.1 variant of concern. Data from the Phase 2/3 trial found that a booster dose of both Omicron-adapted vaccine candidates elicited a substantially higher immune response against Omicron BA.1 as compared to the companies’ current COV...
Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and ...
Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™ Late-breaking data from the double-blind portion of the noninvasive Phase 3 MAESTRO NAFLD-1 study show resmetirom to be safe and well-tolerated and to reduce liver fat, fibrosis measures on FibroScan and MRE, and liver enzymes, as well as multiple atherogenic lipidsIn NASH patients with well-compensated cirrhosis, resmetirom: was safe and well toleratedreduced liver fat, LDL-C, and other atherogenic lipidsreduced noninvasive measures of liver fibrosis and liv...
Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis...
Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B Program – Results from ongoing trials of VIR-2218 and VIR-3434 presented at the International Liver Congress™ (ILC) 2022 demonstrate durable reductions in hepatitis B surface antigen with no safety signals – – Company expects to dose first patient in Part B of the Phase 2 MARCH trial by the end of June – SAN FRANCISCO, June 25, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from its robust hepatitis B virus (HBV) clinical trial program, including results from an ongoing Phas...
Central Hydropower Jsc: 1 director
A director at Central Hydropower Jsc bought 500,000 shares at 0.000VND and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...
Champion Bear Resources Ltd: 1 director
A director at Champion Bear Resources Ltd maiden bought 900,000 shares at 0.100CAD and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the l...
E Automotive Inc: 1 director
A director at E Automotive Inc bought 1,216,300 shares at 4.500CAD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
Keon Capital Inc: 2 directors
Three Directors at Keon Capital Inc bought/subscribed to/sold 816,240 shares at 0.250CAD. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over th...
Lundin Mining Corporation: 1 director
Two Directors at Lundin Mining Corporation bought 517,300 shares at between 8.480CAD and 9.166CAD. The significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's director...
Gayatri Bioorganics Ltd: 1 director
A director at Gayatri Bioorganics Ltd sold 5,000,000 shares at 0.000INR and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
Paramount Resources Ltd: 1 director
A director at Paramount Resources Ltd bought 30,000 shares at 30.967CAD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...
Tiscali Spa: 1 director
A director at Tiscali Spa bought 43,646,210 shares at 0.012EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Nuvoco Vistas Corporation Ltd: 1 director
A director at Nuvoco Vistas Corporation Ltd bought 100,000 shares at 289.190INR and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last...
MilDef Group AB: 1 director
A director at MilDef Group AB sold 440,800 shares at 17.000SEK and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL Int...
Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB-836 Clinical Update AB-729, our RNAi therapeutic, provided robust and comparable HBsAg declines in both HBeAg+ and HBeAg- patients 50% (16 out of 32) of patients maintained HBsAg levels below 100 IU/mL 24 weeks after their last AB-729 dose In the first five patients who discontinued both AB-729 and NA therapy after meeting stopping criteria, there has been no evidence of virologic or clinical relapse in 8-24 weeks of follow-up Preliminary data to date have shown that AB-...
Immunocore announces the presentation of initial data from the Phase 1...
Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™ PRESS RELEASE Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™ IMC-I109V, T cell receptor bispecific, targets an envelope antigen Single Ascending Dose portion of Phase 1 study to evaluate safety, antiviral activity, and pharmacokinetics In the initial cohort, HBsAg declines and ALT elevations indicated that a single, very low dose of IM...
Guangdong Jia Yuan Technology Shares Co Ltd: 1 director
A director at Guangdong Jia Yuan Technology Shares Co Ltd sold 480,000 shares at 68.400CNY and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ov...
Shenzhen Kingdom Technology Co: 1 director
A director at Shenzhen Kingdom Technology Co sold 1,000,000 shares at 9.780CNY and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last ...
KNR Constructions Limited: 1 director
A director at KNR Constructions Limited bought 200,000 shares at 220.500INR and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...
Just Dial Ltd: 1 director
A director at Just Dial Ltd bought 4,000 shares at 541.830INR and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.